But although the drug, called finasteride, caused a 25 % reduction in prostate cancer, it also boosted the risk of
aggressive prostate cancer among those diagnosed with the disease.
Not exact matches
Patients with
aggressive prostate cancer, the second - leading cause of
cancer deaths
among men, had RNase L abnormalities too.
The findings also hint that in coming years, it may be possible to use the panel not just
among men with advanced disease but to distinguish between men who develop the slower growing type of
prostate cancer from the more
aggressive type.